Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
PLoS Pathog ; 17(9): e1009871, 2021 09.
Article in English | MEDLINE | ID: mdl-34555123

ABSTRACT

HIV cerebrospinal fluid (CSF) escape, where HIV is suppressed in blood but detectable in CSF, occurs when HIV persists in the CNS despite antiretroviral therapy (ART). To determine the virus producing cell type and whether lowered CSF ART levels are responsible for CSF escape, we collected blood and CSF from 156 neurosymptomatic participants from Durban, South Africa. We observed that 28% of participants with an undetectable HIV blood viral load showed CSF escape. We detected host cell surface markers on the HIV envelope to determine the cellular source of HIV in participants on the first line regimen of efavirenz, emtricitabine, and tenofovir. We confirmed CD26 as a marker which could differentiate between T cells and macrophages and microglia, and quantified CD26 levels on the virion surface, comparing the result to virus from in vitro infected T cells or macrophages. The measured CD26 level was consistent with the presence of T cell produced virus. We found no significant differences in ART concentrations between CSF escape and fully suppressed individuals in CSF or blood, and did not observe a clear association with drug resistance mutations in CSF virus which would allow HIV to replicate. Hence, CSF HIV in the face of ART may at least partly originate in CD4+ T cell populations.


Subject(s)
Anti-HIV Agents/therapeutic use , HIV Infections/cerebrospinal fluid , HIV Infections/drug therapy , HIV Infections/virology , T-Lymphocytes/virology , Adult , Alkynes/therapeutic use , Benzoxazines/therapeutic use , Cyclopropanes/therapeutic use , Emtricitabine/therapeutic use , Female , HIV-1 , Humans , Male , Middle Aged , Tenofovir/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL